Johnson & Johnson Lifts 2025 Outlook

Johnson & Johnson reported robust Q2 2025 results, with sales of $23.7 billion and adjusted EPS of $2.77, leading to an upward revision of full-year 2025 guidance for both sales and EPS. Despite a significant 43.2% revenue decline from Stelara due to biosimilar competition, the company demonstrated strong operational resilience, with innovative medicine sales rising 3.8% (excluding Stelara, 90% of the business grew 15.5%) and medtech sales increasing 6.1%, notably a 22% surge in cardiovascular. Strategic growth in oncology, aiming for global leadership by 2030 with promising assets like TAR-200, and continued MedTech acceleration driven by acquisitions and pipeline progress, position J&J to sustain long-term earnings power and re-rate as a diversified growth platform despite patent expirations.

Analysis

Johnson & Johnson delivered robust Q2 2025 results, demonstrating significant operational strength that more than compensated for the anticipated impact of Stelara's loss of exclusivity. The company reported a 4.6% increase in sales to $23.7 billion and raised its full-year 2025 guidance for both sales and adjusted EPS, signaling management's confidence in sustained momentum. Despite a 43.2% revenue decline from Stelara, which reduced top-line growth by 710 basis points, the underlying portfolio's health is evident in the 15.5% operational growth across the other 90% of the business. Key growth was driven by the Innovative Medicine division, where 13 brands posted double-digit growth and the oncology franchise expanded by 22.3%, and the MedTech division, which saw 6.1% operational growth led by a 22% surge in its cardiovascular segment following the successful integration of recent acquisitions. Management has set an ambitious target to lead the oncology market by 2030, highlighting a significant valuation disconnect in assets like TAR-200, for which internal forecasts far exceed market consensus. The combination of resilient diversified growth, strategic M&A execution in MedTech, and a pipeline of near-term catalysts positions the company to successfully navigate patent cliffs and accelerate growth in the second half of 2025.

Key Decisions for Investors

• Investors should look beyond the Stelara revenue decline and focus on the underlying 15.5% growth in the core business, as the raised full-year guidance suggests the company has successfully navigated the patent cliff and maintains strong earnings power.
• Monitor upcoming catalysts in the second half of 2025, particularly the approval and launch of TAR-200 for bladder cancer, as management has indicated its potential to significantly outperform current Street expectations and could act as a key re-rating event for the stock.
• The MedTech segment's performance, especially the 22% growth in cardiovascular, should be closely watched as a primary validation of the company's M&A strategy and a critical driver for achieving its long-term, above-market growth objectives.